Allogene Therapeutics (ALLO) Net Cash Flow (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Net Cash Flow data on file, last reported at -$21.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 34.75% year-over-year to -$21.4 million; the trailing twelve-month figure through Mar 2026 stood at -$12.1 million (down 41.5% YoY), and the FY2025 full-year result was -$23.5 million, down 196.46% from the prior year.
• Net Cash Flow declined to -$21.4 million in Q1 2026, from $13.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $119.6 million in Q2 2024 to a low of -$119.4 million in Q3 2024.
• A 5-year average of -$8.4 million and a median of -$12.5 million in 2022 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 288.89% in 2023, while the deepest fall reached 294.36% in 2023.
• Tracing ALLO's Net Cash Flow over 5 years: stood at -$12.5 million in 2022, then surged by 211.69% to $13.9 million in 2023, then soared by 72.4% to $24.0 million in 2024, then slumped by 42.15% to $13.9 million in 2025, then sank by 254.11% to -$21.4 million in 2026.
• Business Quant data shows ALLO's Net Cash Flow at -$21.4 million in Q1 2026, $13.9 million in Q4 2025, and -$14.5 million in Q3 2025.